Standout Papers

Design and validation of a histological scoring system for nonalcoholic fatty liver disease† 2005 2026 2012 2019 8.2k
  1. Design and validation of a histological scoring system for nonalcoholic fatty liver disease† (2005)
    David E. Kleiner, Elizabeth M. Brunt et al. Hepatology
  2. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (2010)
    Arun J. Sanyal, Naga Chalasani et al. New England Journal of Medicine
  3. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (2015)
    Paul Angulo, David E. Kleiner et al. Gastroenterology
  4. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (2014)
    Brent A. Neuschwander‐Tetri, Rohit Loomba et al. The Lancet
  5. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (2023)
    Mary E. Rinella, Brent A. Neuschwander‐Tetri et al. Hepatology
  6. Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis (2009)
    Kittichai Promrat, David E. Kleiner et al. Hepatology
  7. Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §Δ (2010)
    Elizabeth M. Brunt, David E. Kleiner et al. Hepatology
  8. Quantitative Zymography: Detection of Picogram Quantities of Gelatinases (1994)
    David E. Kleiner, William G. Stetler‐Stevenson Analytical Biochemistry
  9. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 (2006)
    Joseph Blansfield, Khoi Q. Tran et al. Journal of Clinical Oncology
  10. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease (2021)
    Arun J. Sanyal, Mark L. Van Natta et al. New England Journal of Medicine
  11. Matrix metalloproteinases and metastasis (1999)
    David E. Kleiner, William G. Stetler‐Stevenson Cancer Chemotherapy and Pharmacology
  12. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡ (2004)
    Kittichai Promrat, Glen Lutchman et al. Hepatology
  13. Endpoints and clinical trial design for nonalcoholic steatohepatitis (2011)
    Arun J. Sanyal, Elizabeth M. Brunt et al. Hepatology
  14. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis (2016)
    Chi Ma, Aparna H. Kesarwala et al. Nature
  15. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis (1993)
    William G. Stetler‐Stevenson, Lance A. Liotta et al. The FASEB Journal
  16. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer (2019)
    Lichun Ma, Maria O. Hernandez et al. Cancer Cell
  17. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease (2018)
    Mohammad Shadab Siddiqui, Raj Vuppalanchi et al. Clinical Gastroenterology and Hepatology
  18. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series (2020)
    Amy Rapkiewicz, Xingchen Mai et al. EClinicalMedicine
  19. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease (2019)
    David E. Kleiner, Elizabeth M. Brunt et al. JAMA Network Open
  20. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma (2021)
    Lichun Ma, Limin Wang et al. Journal of Hepatology

Immediate Impact

6 by Nobel laureates 8 from Science/Nature 143 standout
Sub-graph 1 of 20

Citing Papers

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
2024 Standout
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
2023 Standout

Works of David E. Kleiner being referenced

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
2005 Standout
and 5 more

Author Peers

Author Last Decade Papers Cites
David E. Kleiner 31134 17152 6645 10259 510 49.1k
Anna Mae Diehl 34550 15918 3095 14288 405 50.2k
Scott L. Friedman 31616 30129 5973 4749 431 60.2k
David A. Brenner 26184 21617 4957 4230 507 58.1k
Elizabeth M. Brunt 38092 17176 3442 15206 268 48.9k
Vincent Wai‐Sun Wong 31784 20258 2219 8261 619 42.6k
Frank Tacke 21618 15955 4786 3219 695 43.6k
Rohit Loomba 38376 19761 2530 13696 687 47.8k
Pierre Bédossa 27273 21759 2918 3912 506 37.5k
Kazuaki Chayama 15457 14718 7216 2608 1.4k 44.3k
Herbert Tilg 17363 4777 3519 5394 442 38.5k

All Works

Loading papers...

Rankless by CCL
2026